Evolus, Inc. (EOLS)
NasdaqGM · USD · Healthcare · Drug Manufacturers - Specialty & Generic
$7.17 (+2.28%) as of
Key statistics
- Market cap
- 473.58M
- Forward P/E
- 24.51
- EPS (TTM)
- -0.53
- Dividend yield
- 0.00%
- 52-week range
- 3.86 – 9.31
- Beta
- 1.34
- Revenue (TTM)
- 316.49M
- Profit margin
- -10.85%
- Analyst target
- $15.00
- Volume
- 430.11k
About Evolus, Inc.
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Newport Beach, CA, United States
- Employees
- 353
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.